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Abstract 
 
The neuromodulatory peptide somatostatin-14 (SRIF) plays an important inhibitory role in epilepsy, 
but little is known on the signalling mechanisms coupled to this effect of SRIF. We have previously 
demonstrated that SRIF induces reduction of epileptiform bursting in a model of interictal-like 
activity in mouse hippocampal slices. In this same model, we investigated whether the 
cyclooxygenase 2 (COX-2)/prostaglandin E2 (PGE2) pathway is part of those signalling 
mechanisms mediating SRIF anti-epileptic actions. Both the expression of COX-2 (mRNA and 
protein) and the endogenous release of PGE2 increased in concomitance with epileptiform bursting. 
In particular, COX-2 protein increased in CA1/CA3 pyramidal layer and in the granular layer of the 
dentate gyrus. In addition, the selective inhibition of COX-2 by NS-398 markedly decreased 
endogenous PGE2 release induced by epileptiform bursting and the epileptiform bursting itself. 
Similar effects on epileptiform bursting were obtained with another COX-2 inhibitor, i.e., 
meloxicam. SRIF application counteracted the increase of both COX-2 expression and PGE2 
release which occurred in concomitance with epileptiform bursting. Interestingly, SRIF and NS-398 
comparably reduced epileptiform bursting in a non-additive manner and PGE2 abolished the 
inhibitory effect of SRIF on epileptiform bursting. These results demonstrate that: i) the COX-
2/PGE2 pathway facilitates epileptiform bursting; and ii) SRIF exerts an anti-epileptic role by 
coupling to the COX-2/PGE2 pathway. In conclusion, we have identified a key set of signalling 
events that underlie anti-convulsant effects of SRIF in a mouse model of hippocampal bursting, thus 
providing useful data not only to identify alternative intervention points for the modulation of SRIF 
function, but also to exploit new chemical space for drug-like molecules. 
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1. Introduction 
The peptide somatostatin-14, or SRIF (somatotropin release inhibiting factor), is abundantly 
expressed in mammalian neurons. It is considered as a neuromodulatory agent in the central 
nervous system, and a variety of studies provide the basis for the use of SRIF analogues as 
therapeutics in various psychiatric and neurological disorders (Cervia and Bagnoli, 2007; 
Weckbecker et al., 2003). SRIF is expressed by hippocampal interneurons, while functional data of 
the rodent hippocampus have provided compelling evidence that SRIF plays an important role in 
epilepsy (Binaschi et al., 2003; Jinno and Kosaka, 2004; Matyas et al., 2004; Vezzani and Hoyer, 
1999). Generally, in selected regions of the hippocampus, the acute effects of SRIF compounds on 
synaptic transmission are largely inhibitory (Binaschi et al., 2003; Tallent and Siggins, 1999; 
Vezzani and Hoyer, 1999). In addition, SRIF inhibition of epileptiform bursting has been 
demonstrated in mouse CA1 and CA3 regions (Cammalleri et al., 2004, 2006; Cervia et al., 2005a). 
There is a general agreement that the pleiotropic functions of SRIF are a result of the multiple 
signalling actions of its five G-protein coupled receptors, but our current understanding of such 
signalling in native cells/tissues reflects a rather complicated picture (Cervia and Bagnoli, 2007). In 
the mouse hippocampus, for instance, the SRIF-mediated reduction of epileptiform bursting has 
been shown to parallel the SRIF-mediated inhibition of adenylyl cyclase activity (Cammalleri et al., 
2004, 2006), however, the signalling mechanisms mediating SRIF actions on hippocampal 
epileptiform activity remain largely to be clarified. 
Specific signalling mechanisms have been implicated in hippocampal excitability, including 
epileptiform activity (McNamara et al., 2006). For instance, arachidonic acid (AA) is released from 
neuronal membrane phospholipids during seizures and the phospholipase A2 
(PLA2)/AA/cyclooxygenases (COXs)/prostaglandins (PGs) cascade appears to play a key role in 
epileptogenesis (for a review see Cole- Edwards and Bazan, 2005; Hewett et al., 2006; Phillis et al., 
2006). The PLA2 enzyme hydrolyzes triglycerol to form AA. Free AA is a substrate for different 
enzymes, including COXs (which exists in two different isoforms: COX-1 and COX-2). In the 
central nervous system, COX-1 has an ubiquitary distribution in both glia and neurons, whereas 
COX-2 is constitutively expressed primarily in neurons (Hewett et al., 2006). In particular, 
constitutive COX-2 protein has been found in selected brain regions, including the hippocampus, 
where it appears to be coupled to excitatory neuronal activity, and produces PGs required for 
normal neuronal functions. Among PGs, PGE2 plays a central role in the modulation of 
hippocampal activity (Chen and Bazan, 2005b). In addition, an important role of COX-2 and the 
COX-2-generated PGE2 in hippocampal synaptic signalling and seizures has been recently 
documented (Chen and Bazan, 2005a; Chen et al., 2002; Kawaguchi et al., 2005; Sang et al., 2005; 
Takemiya et al., 2003, 2006; Tu and Bazan, 2003; Voutsinos-Porche et al., 2004). 
In the present study, our hypothesis was that the COX-2 pathway is part of those signalling 
mechanisms mediating the SRIF inhibition of mouse hippocampal activity. Supporting this 
hypothesis, an important component in transduction mechanisms of SRIF in native cell/tissues as 
well as in recombinant systems is the modulation of PLA2 pathway (Cervia and Bagnoli, 2007; 
Cervia et al., 2005b). In our work, we used a well-established model of epileptiform bursting 
(interictal-like activity) induced in mouse hippocampal slices by Mg2þ-free medium with 4-
aminopyridine (0 Mg2þ/ 4-AP) (Cammalleri et al., 2004, 2006; Cervia et al., 2005a). In this model, 
we first evaluated whether the expression of COX-2 and the endogenous release of PGE2 are 
modified by 0 Mg2 þ/4-AP either alone or in combination with SRIF. We then studied the effects of 
COX-2 inhibition on both PGE2 release and epileptiform bursting as well as the possible 
correlation between COX-2/PGE2 modulation and SRIF inhibitory action on epileptiform bursting. 
 
2. Methods 
2.1. Animals 
Experiments were performed on 64 mice (C57BL/6 strain) of both sexes at 6e8 weeks after birth 
(20e30 g body weight). Animals were kept in a regulated environment (23 _ 1 _C, 50 _ 5% 
humidity) with a 12 h light/dark cycle (lights on at 8 a.m.) with food and water ad lib. In all 
experiments, mice were anaesthetised with halothane (4%). Experiments were performed in 
compliance with the Italian law on animal care N_ 116/1992 and in accordance with the European 
Community Council Directive (EEC/609/86). All efforts were made to reduce both animal suffering 
and the number of animals used. 
 
2.2. Preparation of hippocampal slices 
Slices of dorsal hippocampus were prepared as previously described (Cammalleri et al., 2004, 2006; 
Cervia et al., 2005a). Briefly, mice were anaesthetised and decapitated. Their brains were rapidly 
removed, placed in ice-cold artificial cerebrospinal fluid (aCSF) and gassed with 95% O2 and 5% 
CO2. The composition of aCSF was (in mM): NaCl, 130; KCl, 3.5; NaH2PO4, 1.25; MgSO4 
7H2O, 1.5; CaCl2 2H2O, 2; NaHCO3, 24; glucose, 10; pH 7.4. Transverse hippocampal slices (400 
mm) were prepared with the use of a vibratome (Campden Instruments, Loughborough, UK) and 
incubated for 1 h at room temperature in aCSF. For experiments in basal conditions, hippocampal 
slices were then placed in aCSF for additional 3 h. Alternatively, they were placed for 3 h in 0 
Mg2þ/4-AP consisting of Mg2þ-free aCSF with 50 mM 4-AP to induce epileptiform bursting 
(interictal-like activity) in agreement with previous works (Cammalleri et al., 2004, 2006; Cervia et 
al., 2005a; Sanna et al., 2000). Indeed, depletion of extracellular Mg2þ from hippocampal slices 
results in enhancement of synaptically evoked responses in CA1 and CA3 regions and the 
appearance of spontaneous paroxysmal depolarisation shifts in both areas, whereas 4-AP induces 
epileptiform activity by enhancing the release of excitatory and inhibitory amino acids (Avoli, 
2001). When indicated, the COX inhibitors NS-398 or meloxicam were applied 2 h and 20 min, 
respectively, before the end of the incubation in 0 Mg2þ/4-AP. 
 
2.3. Semi-quantitative reverse transcription (RT)-PCR 
After 3 h slice incubation in aCSF or 0 Mg2þ/4-AP, the medium was replaced with fresh medium 
consisting of aCSF, 0 Mg2þ/4-AP or 0 Mg2þ/4- AP þ SRIF for additional 20 min. For each 
experimental condition, 4 slices from different animals were then collected and total RNA 
extraction was performed in Trizol reagent (Invitrogen, Milano, Italy). After solubilization in 
diethyl pyrocarbonate-treated water, total RNA was quantified by Bio-Rad SmartSpec 3000 
spectrophotometer (Hercules, CA, USA). First-strand cDNA was generated from 2 mg of total RNA 
using random primers and the reverse transcriptase of Moloney murine leukemia virus (Invitrogen, 
Milano, Italy). As shown in Table 1, primer pairs for COX-2 were designed to hybridise to unique 
regions of the respective gene sequence. Primers for cyclophilin B, a stable mRNA during epilepsy 
(Cammalleri et al., 2004, 2006), was used as an internal standard. The PCR reactions were carried 
out using 1 ml of cDNA in a 25 ml total volume of PCR buffer (Invitrogen, Milano, Italy), 
containing 1.5 mM MgCl2, 200 mM dNTPs, and 400 nM of appropriate primers. Taq polymerase 
(0.5 U, Invitrogen) was also added. The amplification reactions were carried out in a thermal 
gradient cycler (Bio-Rad, Hercules, CA, USA) for 30 cycles. Each cycle consisted of denaturation 
for 60 s at 94 _C, annealing for 60 s at 55 _C (COX-2) or 60 _C (cyclophilin B), and an extension 
for 60 s at 72 _C. A final extension step at 72 _C for 10 min terminated the amplification. For each 
amplification, two types of controls were performed: (i) RT-PCR mixture with no reverse 
transcriptase to control for genomic DNA contamination; and (ii) PCR mixture with no cDNA 
template, to check for possible external contamination. A 5 ml sample of the PCR reaction was 
electrophoresed on an ethidium bromide-containing 2% agarose gel by the use of the Bio-Rad Sub-
cell GT system. After migration, bands corresponding to the amplified products were analysed with 
Gel Doc 2000 System equipped with Quantity One software (Bio-Rad). Semi-quantitative analysis 
of PCR products was performed by measuring the optical intensity of the bands corresponding to 
COX-2 with respect to the optical intensity of the band corresponding to the respective cyclophilin 
B. 
 
2.4. Immunohistochemistry 
After 3 h slice incubation in aCSF or 0 Mg2þ/4-AP, the medium was replaced with fresh medium 
consisting of aCSF, 0 Mg2þ/4-AP or 0 Mg2þ/4- AP þ SRIF for additional 20 min. Using published 
protocols (Cammalleri et al., 2006), the hippocampal slices were then fixed for 1 h in 4% 
paraformaldehyde in 0.1 M phosphate buffer (PB) at 4 _C. They were then rinsed in 0.1 M PB and 
incubated for 48 h in 1:200 of a rabbit polyclonal antibody directed against COX-2 (Yamagata et 
al., 1993) diluted in 0.1 M PB containing 0.3% Triton X-100 at 4 _C. The slices were then rinsed in 
0.1 M PB and incubated overnight in secondary antibody conjugated with Alexa Fluor 488 at a 
dilution of 1:200 in 0.1 M PB containing 0.3% Triton X-100. Finally, the slices were rinsed in 0.1 
M PB, mounted on gelatin-coated glass slides and coverslipped in a 0.1 M PB-glycerine mixture. 
The specificity of COX- 2-immunoreactivity (-ir) was evaluated by omitting the primary antibody. 
The slices were examined with a confocal laser scanning microscope (Leica Microsystems 
Heidelberg, Mannheim, Germany) using 10_ or 40_ objective lens. Optical sections were scanned 
through the thickness of each slice, and single 1 mm thick optical sections at the same 
predetermined z-axis were collected for the analysis of COX-2-ir intensity. A method for measuring 
immunofluorescence intensity from blindcoded confocal images is detailed in Cammalleri et al. 
(2006), adapted from Gazzaley et al. (1997, 1996a,b). The software package KS-300 (Carl Zeiss 
Vision, Mu¨nchen-Hallbergmoos, Germany) was used to determine the average pixel intensity (grey 
scale) of single fields in the stratum pyramidale of CA1 and CA3 regions, and in the granular layer 
of the dentate gyrus. Within each field, the contribution of unlabelled portions was removed, 
normalizing the data to the background fluorescence. Mean intensity values for each field were 
expressed as a percentage of the average fluorescence intensity of the corresponding field of 
hippocampal slices in basal conditions (aCSF). 
 2.5. PGE2 release assay 
PGE2 release was measured in hippocampal slices treated for 3 h in aCSF either alone or in 
combination with 0 Mg2þ/4-AP, without or with additional treatment with SRIF for 20 min. In 
some experiments, PGE2 release was also measured in aCSF- or 0 Mg2þ/4-AP-treated slices in the 
presence of increasing concentrations of the COX-2 inhibitor NS-398 which was applied 2 h before 
the end of the incubation in either aCSF or 0 Mg2þ/4-AP. For each experimental condition, samples 
including 4 slices from different animals were collected and were centrifuged at 2000 _ g for 5 min. 
After centrifugation, the clear incubation medium (3 ml for each sample) was used for 
measurements of PGE2 release according to previous studies in the rat epileptic hippocampus 
(Ajmone-Cat et al., 2006). In particular, PGE2 levels were detected using the high sensitivity 
colorimetric enzyme immunoassays (EIA) kit (Cayman Chemical, Inalco, Milano, Italy) according 
to the manufacturer’s instructions. All measurements were run in triplicate for each sample. PGE2 
concentration was determined spectrophotometrically by Victor3v microplate reader (Perkin- 
Elmer, Norwalk, CT, USA). Data were expressed as pg of PGE2 in the medium/ mg of the 
respective wet tissue. NS-398 inhibition of PGE2 release in aCSF-treated slices and in 0 Mg2þ/4-
AP-treated slices was calculated as a percentage of the basal or of the 0 Mg2þ/4-AP-induced PGE2 
release, respectively. 
 
2.6. Electrophysiology 
Using published protocols (Cammalleri et al., 2004, 2006; Cervia et al., 2005a), at the end of the 
incubation in 0 Mg2þ/4-AP hippocampal slices were transferred to an interface recording chamber 
containing fresh 0 Mg2þ/ 4-AP either in the absence and in the presence of NS-398 or meloxicam 
without or with SRIF. SRIF and NS-398 were also applied sequentially during the recording. 
Extracellular recordings of hippocampal discharge were performed from the stratum pyramidale of 
the CA1 region by using 2e5 MU microelectrodes filled with aCSF. Epileptiform bursts induced by 
0 Mg2þ/4-AP were amplified with an Axoclamp-2B amplifier (Axon Instruments, Foster City, CA, 
USA), filtered (DC 3e10 kHz) and displayed on an oscilloscope. Signals were recorded for 20 min. 
The interval between SRIF application and the recording of an observable effect was 6e8 min. All 
traces were analysed using the LabView software package (National Instruments, Austin, TX, 
USA). The data represent the mean discharge frequency (burst frequency/min) over the recording 
period. Inhibition of burst frequency was calculated as a percentage of the burst frequency in the 
presence of 0 Mg2þ/4-AP. 
 
2.7. Data analysis 
Upon verification of normal distribution, statistical significance of data was evaluated using 
ANOVA followed by multiple comparison Bonferroni’s posttest. The GraphPad Prism software 
package (Graph Software, San Diego, CA, USA) was used. Differences with p < 0.05 were 
considered significant. Emax (maximum percentage effect) and IC50 (the concentration producing 
half the maximum inhibitory effect) were determined by non-linear regression curve analysis of the 
concentration-effect responses using GraphPad Prism. The results were expressed as means _ SEM 
of the indicated n values. 
 
2.8. Chemicals 
SRIF was purchased from Bachem (Bubendorf, Switzerland). Primer pairs for COX-2 and 
cyclophilin B were purchased from Eurobio (Les Ulis, France). The rabbit polyclonal antibody 
directed against COX-2 was purchased from Chemicon (Temecula, CA, USA). Secondary antibody 
conjugated with Alexa Fluor 488 was purchased from Molecular Probes (Eugene, OR, USA). 
Where not specified, chemicals and reagents were obtained from Sigma-Aldrich (St. Louis, MO, 
USA). 
 
3. Results 
3.1. SRIF affects the increase in COX-2 expression induced by epileptiform bursting 
COX-2 expression was measured in aCSF-treated (basal condition) as well as in 0 Mg2þ/4-AP-
treated slices (an experimental model of epileptiform bursting activity) both in the absence and in 
the presence of SRIF (20 min treatment). SRIF was used at 1 mM, a concentration giving maximal 
receptor occupancy in our system (Cammalleri et al., 2004, 2006; Cervia et al., 2005a), that was 
also used in previous studies on the effects of SRIF compounds in the rodent hippocampus (Boehm 
and Betz, 1997; Cammalleri et al., 2004, 2006; Moneta et al., 2002; Schweitzer et al., 1998; Tallent 
and Siggins, 1997, 1999). By means of RT-PCR, we found that 0 Mg2þ/4-AP treatment increased 
COX-2 mRNA levels by 27 _ 3.4% (with respect to aCSF-treated slices) (Fig. 1). In the presence of 
SRIF, this increase was abolished. As shown in the confocal images of Fig. 2A, slices of the mouse 
hippocampus slices treated with aCSF, revealed constitutive COX-2 protein expression in many 
areas of this brain region, consistent with previous reports of mice and rats (Kawaguchi et al., 2005; 
Takemiya et al., 2003; Tu and Bazan, 2003; Voutsinos-Porche et al., 2004). In particular, prominent 
staining was in the pyramidal layer of all hippocampal areas as well as in the granular layer of the 
dentate gyrus. Higher magnifications (insets of Fig. 2A) revealed immunolabeling of pyramidal cell 
somata, of their dendritic fields in the stratum radiatum, of granular cell somata and of scattered 
cells located in the sub-pyramidal layer of the stratum oriens and in the subgranular layer of the 
stratum moleculare. After 0 Mg2þ/4-AP treatment, COX-2-ir increased significantly when 
compared to basal conditions and this increase was reduced significantly by SRIF (Fig. 2B). In 
particular, as shown in Fig. 2C, COX-2- ir significantly increased in the pyramidal layers of CA1 
(17 _ 2%) and CA3 (24 _ 3%) and in the granular layer of dentate gyrus (37 _ 3%), while SRIF 
completely restored COX-2-ir in CA1/CA3 regions and partially in the dentate gyrus. 
 
3.2. SRIF affects the increase in PGE2 release induced by epileptiform bursting 
EIA measurements of PGE2 release in mouse hippocampal slices revealed that 0 Mg2þ/4-AP 
treatment increased the release of PGE2 by 26 _ 4.5% (with respect to aCSF-treated slices) (Fig. 3). 
After the application of 1 mM SRIF for 20 min, this increase was no longer observed. 
 
3.3. Inhibition of COX-2/PGE2 affects epileptiform bursting 
In agreement with previous papers (Chen and Bazan, 2005a; Chen et al., 2002; Sang et al., 2005; 
Takemiya et al., 2006), the selective COX-2 inhibitor NS-398 (Vane et al., 1998) was used in 
mouse hippocampal slices treated with 0 Mg2 þ/4-AP. According to Chen and Bazan (2005a), the 
slices were pretreated with NS-398 for at least 2 h to allow the inhibition of PGE2 formation during 
the time course of the experiment. As shown in Fig. 4A, NS-398 produced a concentration- 
dependent inhibition of 0 Mg2þ/4-AP-stimulated PGE2 release with an IC50 of 7.05 mM and an 
Emax of 85%. The effects of COX-2 inhibition on PGE2 formation in slices treated with aCSF were 
also examined (Fig. 4B). In these conditions, an inhibitory effect of NS-398 on PGE2 release (24 _ 
4.1%) was detected only at the highest concentration tested (50 mM). 
To determine whether COX-2 participates in epileptiform bursting, NS-398 effects on hippocampal 
discharge extracellularly recorded from slices treated with 0 Mg2þ/4-AP were also investigated 
(Figs. 5A,B). As expected, the frequency (29.7 _ 0.2/min) and the duration (150e200 msec) of the 
bursting were consistent with previous data (Cammalleri et al., 2004, 2006; Cervia et al., 2005a). In 
addition, NS-398 (2 h pretreatment and continuously perfused in the recording bath) produced a 
concentration-dependent inhibition of 0 Mg2 þ/4-AP-induced bursting frequency with an IC50 of 
1.86 mM and an Emax of 36%. Another selective COX-2 inhibitor structurally different from NS-
398 was also used, i.e., meloxicam (Vane et al., 1998). Hippocampal slices were preincubated with 
increasing concentrations of meloxicam for 20 min, according to previous studies (Slanina and 
Schweitzer, 2005). As shown in Figs. 5AeC, meloxicam (20 min pretreatment and continuously 
perfused in the recording bath) produced a concentration-dependent inhibition of 0 Mg2 þ/4-AP-
induced bursting frequency with an IC50 of 9.24 mM and an Emax of 34%. 
 3.4. SRIF and NS-398 affect epileptiform bursting in a non-additive manner 
In another set of experiments (Fig. 6A), we found that the application of 1 mM SRIF (20 min) 
reduced the 0 Mg2þ/4-APinduced bursting frequency of mouse hippocampal slices by 31 _ 1.7%, in 
agreement with previous reports (Cammalleri et al., 2004, 2006; Cervia et al., 2005a). The effects of 
NS-398 either alone or in combination with SRIF on Mg2þ/4-AP-induced bursting were also 
investigated. In agreement with the pharmacological parameters reported above, NS-398 was used 
at 10 mM, a concentration higher than the reported IC50 for COX-2, but lower than the IC50 for 
COX-1 (Vane et al., 1998). NS-398 (2 h pretreatment and continuously perfused in the recording 
bath) decreased the Mg2þ/4-AP-induced bursting frequency by 36 _ 0.7% and this inhibitory effect 
remained unchanged after the application of 1 mM SRIF for 20 min. NS- 398 was also applied after 
SRIF and superfused for 30 min in the recording bath. Results of these experiments demonstrated 
that sequential application of SRIF and NS-398 did not alter the inhibitory effect of SRIF alone. In 
order to validate this experimental setting, we demonstrated that NS-398 effects on Mg2þ/4-AP-
induced bursting frequency obtained at 10 mMafter 30 min superfusion in the recording bath (39 _ 
0.5% of inhibition) were similar to those achieved after 2 h pretreatment (Fig. 6B). 
 
3.5. PGE2 abolishes the inhibitory effect of SRIF on epileptiform bursting 
The involvement of PGE2 in the modulation of hippocampal bursting was further supported by 
results from experiments with application of exogenous PGE2. PGE2 was applied at 1 mM, a 
concentration which increases membrane excitability of rat hippocampal neurons (Chen and Bazan, 
2005a). As shown in Fig. 7, the sequential application of PGE2 abolished the inhibitory effect of 1 
mM SRIF (20 min) on epileptiform bursting. 
 
4. Discussion 
In the present study, we have examined whether the COX-2 pathway is functionally coupled to the 
SRIF inhibitory action on mouse hippocampal epileptiform bursting. COX enzymes are heme-
containing bis-oxygenases that catalyse the first committed reaction in metabolism of AA, whose 
metabolites (i.e., the PGs) affect a wide spectrum of activities in the nervous system, including 
epileptogenesis (for a review see Cole- Edwards and Bazan, 2005; Hewett et al., 2006; Phillis et al., 
2006). Previous results have reported that, in the mouse and rat hippocampus, COX-2 and/or PGE2 
are increased after seizures in different experimental models (Kawaguchi et al., 2005; Takemiya et 
al., 2003, 2006; Tu and Bazan, 2003). We demonstrate here that, in the mouse hippocampus, the 
expression of COX-2 (at both mRNA and protein level) and the endogenous release of PGE2 
increase in concomitance with epileptiform bursting (interictal-like activity) induced by 0 Mg2þ/4-
AP. In particular, quantitative evaluation of COX-2 immunofluorescent labeling has revealed that 
COX-2 protein increases in the pyramidal layers of CA1/CA3 and in the granular layer of the 
dentate gyrus. Accordingly, in a rat lithium-pilocarpine model of temporal lobe epilepsy, COX-2 
protein has been recently shown to up-regulate in the whole hippocampus (Voutsinos-Porche et al., 
2004). Similarly, COX-2 protein is up-regulated in CA3 and in the dentate gyrus of rats after 
kainate-induced limbic seizures (Kawaguchi et al., 2005). We have also observed that, in the mouse 
hippocampus, the COX inhibitor NS-398 has a slight effect on endogenous PGE2 release in control 
conditions while it markedly decreases endogenous PGE2 release induced by 0 Mg2þ/4-AP with a 
potency 2.4-fold higher than the affinity value reported for the inhibition of COX-1 (Vane et al., 
1998). These results indicate that PGE2 produced during epilepsy is mainly a results of COX-2 
activity. That PGE2 is mainly synthesized by COX-2 has been previously demonstrated in the 
rodent hippocampus (Chen and Bazan, 2005a; Chen et al., 2002; Kawaguchi et al., 2005; Sang et 
al., 2005; Takemiya et al., 2006). Our additional finding that NS-398 drastically reduces 
epileptiform bursting with a potency 4.1-fold higher than the affinity value for the inhibition of 
PGE2 release suggests that, in our system, a relative small degree of COX-2/ PGE2 inhibition is 
required to obtain a significant inhibition of epileptiform bursting. Our data obtained with 
meloxicam, another selective COX-2 inhibitor structurally different from NS-398, further suggest 
the involvement of COX-2 in epileptiform bursting. As recently reviewed by Hewett et al. (2006), 
COX-2 inhibitors seem to differentially attenuate both hippocampal seizures and neurodegenerative 
changes which precede seizure development. In particular, the inhibition by NS-398 of PGE2 
production in the rat hippocampus seizured with kainic acid has been shown to prevent neuronal 
death (Takemiya et al., 2006). In addition, meloxicam was demonstrated to decrease CA1 excitatory 
responses in rat hippocampal slices (Slanina and Schweitzer, 2005). On the other hand, it is 
noteworthy that the outcome of COX-2 inhibition in the epileptic model appears to be dependent, at 
least in part, on the treatment paradigm employed (Gobbo and O’Mara, 2004). Taken together, 
these data demonstrate that, in the mouse hippocampus, the COX-2/PGE2 pathway facilitates 
epileptiform bursting induced by 0 Mg2þ/4-AP and is in line with the concept that COX-2 
inhibition may exert an antiepileptogenic role. 
In the hippocampus, SRIF is present in distinct interneurons and acts in concert with g-
aminobutyric acid (GABA), the primary inhibitory neurotransmitter in the central nervous system 
(which has a central role in epilepsy), with which it is colocalized and sometimes co-released 
(Binaschi et al., 2003; Cossart et al., 2005; Jinno and Kosaka, 2004; Matyas et al., 2004). 
Interneurons are often classified according to neuropeptide content. Recent advances in 
understanding neuropeptide release and physiological actions suggest that the interneuronal system 
of neuropeptides is crucial for maintaining appropriate brain function under normal and 
pathophysiological conditions, including epilepsy (Baraban and Tallent, 2004). Among 
neuropeptides, SRIF is released in characteristic conditions of seizures (Binaschi et al., 2003; 
Vezzani and Hoyer, 1999). In addition, epileptic patients and experimental models of epilepsy 
display loss of SRIF neurons in the hippocampus (Buckmaster et al., 2002; Sun et al., 2007). 
Functionally, the effects of SRIF compounds on excitatory transmission are largely modulatory and 
include a powerful inhibition of excitation (and, sometimes, an increase of the inhibition) in 
selected regions of the hippocampus (Baraban and Tallent, 2004; Binaschi et al., 2003; Tallent and 
Siggins, 1999; Vezzani and Hoyer, 1999). There are recent studies in mouse hilar neurons (often 
among the first lost in hippocampal epilepsy) which indicate that SRIF hyperpolarizes and reduces 
the spike frequency of these cells (Fu and van den Pol, 2007). In the mouse hippocampus, SRIF 
inhibition of epileptiform bursting induced by 0 Mg2þ/4-AP has been shown in CA1 and CA3 
regions (Cammalleri et al., 2004, 2006; Cervia et al., 2005a), but information on signalling 
mediating SRIF actions is still limited (Cervia and Bagnoli, 2007). Here, we present data indicating 
that SRIF exerts an anti-epileptic role in a functional model of hippocampal bursting by negative 
coupling to the COX-2/PGE2 pathway. Among the indirect evidence, we found that, in the mouse 
hippocampus treated with 0 Mg2 þ/4-AP, SRIF counteracts the increase of both COX-2 expression 
and PGE2 release which occurs in concomitance with epileptiform bursting. In addition, SRIF and 
NS-398 comparably reduce epileptiform bursting. Moreover, PGE2 abolished the inhibitory effect 
of SRIF on epileptiform bursting, thus demonstrating that PGE2 takes a serious part in COX- 2 
products. The finding that the effects of SRIF and NS-398 (SRIF applied after NS-398 and vice-
versa) are non-additive suggests that they converge upon signalling mechanisms involving the 
inhibition of COX-2/PGE2, thus providing a direct link (through a pharmacological approach) 
between COX-2/ PGE2 and SRIF. In addition, our data are not entirely consistent with the 
possibility that SRIF may indirectly reduce COX-2/PGE2 as a consequence of the SRIF-induced 
decrease of neuronal activity: if that was the case, a further reduction of epileptiform bursting 
should be seen following SRIF application in the presence of NS-398. Although we cannot exclude 
that such basic effect may take some part in the SRIF-induced modulation of COX-2/PGE2, we 
favour the possibility that, in the mouse hippocampus, SRIF binding to its G-protein coupled 
receptors leads to inhibition of PGE2 through both PLA2 inhibition and downregulation of COX-2 
expression. In this respect, SRIF negative coupling to PLA2/AA pathway has been demonstrated in 
the rat diaphragm (Arias-Diaz et al., 1997), and in rat GC cells (Cervia et al., 2002). As previously 
reported in different experimental models (Boehm and Betz, 1997; Schweitzer et al., 1998; Tallent 
and Siggins, 1997, 1999), SRIF actions in the hippocampus may involve the modulation of 
glutamatergic currents, (i.e., the pharmacologically isolated AMPA and NMDA receptor-mediated 
excitatory synaptic currents) andGABAergic currents. SRIF-induced modulation of different Kþ 
and Ca2þ currents may also occur. In particular, previous experiments performed on postsynaptic 
potentials of CA1 pyramidal cells of the mouse hippocampus treated with 0Mg2þ/4-AP have 
demonstrated that SRIF not only decreases neuronal responsiveness to glutamate 
(AMPAandNMDAcurrents) but also increases inhibitory transmission (GABAA currents) 
(Cammalleri et al., 2006). These effects are paralleled by the SRIF-mediated inhibition of adenylyl 
cyclase activity (Cammalleri et al., 2004, 2006), although a direct involvement of cAMP pathway 
on SRIF actions needs to be further demonstrated. A role of PLA2/AA/COXs/PGs pathway in the 
modulation ofAMPA,NMDAand/orGABAreceptor activity is well established in the hippocampus 
(Brady et al., 2006; Menard et al., 2005a,b; Pepicelli et al., 2005; Schwartz- Bloom and Sah, 2001; 
Shen et al., 2007). Thus, we can speculate that, among the different coupling mechanisms which 
may mediate SRIF modulation of AMPA, NMDA and/or GABAA currents, an important role may 
be ascribed to SRIF negative coupling to the COX-2/PGE2 pathway. This is also in line with recent 
findings in the rat hippocampus, demonstrating that COX-2 mediates the decrease of excitatory 
transmission exerted by neuropeptides other than SRIF such as cannabinoids (Slanina and 
Schweitzer, 2005). In this respect, that cannabinoids can effectively block status epilepticus has 
been recently demonstrated in rat hippocampal neuronal cultures (Deshpande et al., 2007). 
 
5. Remarks 
In conclusion, in this paper we have identified a key set of signalling events that underlie anti-
convulsant effects of SRIF in a mouse model of hippocampal bursting. In particular, our results not 
only confirm that the COX-2/PGE2 pathway is upregulated by seizures, but also demonstrate for 
the first time that the SRIF-induced inhibition of epileptiform bursting involves a downregulation of 
the COX-2/PGE2 pathway. Generally, PGs are a family of structurally related lipid mediators 
playing critical roles in the initiation and modulation of inflammation. In this respect, a SRIF role as 
an anti-inflammatory agent has emerged recently (for ref. see Armani et al., 2007; Szokoloczi et al., 
2005), and it is noteworthy that some anti-inflammatory treatments reduce epileptic activity in 
different animal models of epilepsy and, in some instances, in clinical cases of epilepsy, thus 
opening new perspectives for the pharmacological treatment of seizures (Phillis et al., 2006; 
Vezzani and Granata, 2005). Indeed, available therapy for epilepsy is only symptomatic and often 
ineffective. Therefore, a great deal of effort has been devoted to identifying new antieplectic drugs, 
with mechanisms of action different from those currently in use (Stefan and Feuerstein, 2007; 
Stepien et al., 2005; Wuttke and Lerche, 2006). Thus, elucidation of SRIF signalling in nervous 
system diseases, including epilepsy, warrants further study not only to identify alternative 
intervention points for the modulation of SRIF function, but also to exploit new chemical space for 
drug-like molecules. 
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Figure Legends 
 Fig. 1. Measurements of COX-2 mRNA in hippocampal slices treated with aCSF, 0 Mg2þ/4-AP 
and 0 Mg2þ/4-AP þ1 mM SRIF. Representative RTPCR products corresponding to COX-2 or 
cyclophilin B (internal standard) are shown in the upper panel, whereas the semi-quantitative RT-
PCR analysis is in the lower panel. Each histogram represents the mean _ SEM (bars) of data from 
6 independent experiments. *p < 0.001 vs aCSF (ANOVA followed by Bonferroni’s post-test). 
 
Fig. 2. (A) Regional distribution of COX-2-ir in a hippocampal slice treated with aCSF. This low-
magnification image is a reconstruction of 7 confocal optical sections acquired with a 10_ objective. 
Prominent COX-2 immunostaining was observed in the pyramidal layer (Pyr) of CA1-CA3 and in 
the granular layer (Gr) of the dentate gyrus. As shown in the insets (40_ objective), COX-2-ir could 
be detected in pyramidal cell dendrites in the stratum radiatum (Rad) as well as in scattered 
immunostained somata in the stratum oriens (Or) and in the stratum moleculare (Mol). Scale bars: 
300 mm for the low magnification image, 40 mm for the images in the insets. (B) Representative 
images of the regional distribution of COX-2-ir in hippocampal slices treated with 0 Mg2þ/4-AP 
and 0 Mg2þ/4-AP þ1 mM SRIF. Similar to the image in the upper panel, these images are 
reconstructions from multiple confocal optical sections. Scale bar: 300 mm. (C) Relative 
fluorescence intensity of COX-2-ir in distinct regions of hippocampal slices under the different 
experimental conditions. Each histogram represents the mean _ SEM (bars) of data from 6 
measurements in different fields of 3 independent experiments. *p < 0.01 vs aCSF and #p < 0.05 vs 
the respective 0 Mg2þ/4-AP (ANOVA followed by Bonferroni’s post-test). 
 
Fig. 3. Measurements of PGE2 release in hippocampal slices treated with aCSF, 0 Mg2þ/4-AP and 
0 Mg2þ/4-AP þ1 mM SRIF. Each histogram represents the mean _ SEM (bars) of data from 4 
independent experiments run in triplicate. *p < 0.001 vs aCSF (ANOVA followed by Bonferroni’s 
posttest). 
 
Fig. 4. Measurements of PGE2 release in hippocampal slices treated with 0 Mg2þ/4-AP (A) or in 
aCSF (B) in the presence of increasing concentrations of the COX-2 inhibitor NS-398. The data 
points represent the mean _ SEM of data from 4 independent experiments run in triplicate. 
 
Fig. 5. (A) Measurements of epileptiform bursting in hippocampal slices treated with 0 Mg2þ/4-AP 
in the presence of increasing concentrations of the COX-2 inhibitors NS-398 or meloxicam. The 
data points represent the mean _ SEM of data from 4 independent experiments. (B, C) 
Representative traces depicting electrophysiological recordings of epileptiform bursting. 
 
Fig. 6. (A) Measurements of epileptiform bursting in hippocampal slices treated with 0 Mg2þ/4-AP 
in the absence or in the presence of 1 mM SRIF and/or 10 mM NS-398. Each histogram represents 
the mean _ SEM (bars) of data from 6 independent experiments. *p < 0.001 vs 0 Mg2þ/4-AP 
(ANOVA followed by Bonferroni’s post-test). Representative traces depicting electrophysiological 
recordings of epileptiform bursting are shown in the right panel. (B) Measurements of epileptiform 
bursting in hippocampal slices treated with 0 Mg2þ/4-AP in the presence of 10 mM NS-398 at 
increasing times of superfusion in the recording bath. Each histogram represents the mean _ SEM 
(bars) of data from 4 independent experiments. *p < 0.001 vs 0 Mg2þ/4-AP and xp < 0.01 vs 20 
min superfusion (ANOVA followed by Bonferroni’s post-test). Representative traces depicting 
electrophysiological recordings of epileptiform bursting are shown in the right panel. 
 
Fig. 7. Measurements of epileptiform bursting in hippocampal slices treated with 0 Mg2þ/4-AP in 
the absence or in the presence of 1 mM SRIF and 1 mM PGE2. Each histogram represents the mean 
_ SEM (bars) of data from 4 independent experiments. *p < 0.001 vs 0 Mg2þ/4-AP (ANOVA 
followed by Bonferroni’s posttest). Representative traces depicting electrophysiological recordings 
of epileptiform bursting are shown in the right panel. 
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